Kidney Disease

Your daily dose of the clinical news you may have missed.

Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.

Your daily dose of the clinical news you may have missed.

New study findings raise important questions about how early to initiate therapy to reduce proteinuria and whether even lower levels should be sought to improve CKD outcomes.

Your daily dose of the clinical news you may have missed.

The FDA approved the oral medication to treat anemia in adult patients with chronic kidney disease on dialysis for at least 3 months.

Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Authors: Exclusion of people with CKD from CV medication trials has left significant gaps in understanding the effectiveness of these drugs in a highly vulnerable population.

The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Adults who said they always added extra salt to their food had an 11% higher risk for developing CKD compared with those who never or only rarely added salt, according to new research.

Findings underscore the importance of preventive measures and management of risk factors associated with CKD in adolescents with elevated BMI, report researchers.

Chiadi Ndumele, MD, PhD, MHS, offers 3 thoughts for primary care on incorporating CKM syndrome screening into daily clinical practice.

Experts wrap up their discussion of emerging chronic kidney disease tests and treatments with key takeaways for providers and patients.

Robert Busch, MD, provides his approach on implementing artificial intelligence (AI) testing for chronic kidney disease and offers success stories of this testing and treatment approach.

Experts discuss a new artificial intelligence (AI) tool for earlier staging and management of chronic kidney disease (CKD). They also discuss several studies where this tool was utilized and its overall clinical significance.

Dhiren Patel, PharmD, and Robert Busch, MD, discuss emerging technologies to test and treat patients with chronic kidney disease (CKD) and why these treatments are currently being underutilized.

Experts highlight considerations for patients with chronic kidney disease and other comorbid conditions, particularly diabetes, in terms of screening and preventative care.

Experts discuss key challenges in testing and diagnosing a patient with chronic kidney disease, especially for those who are asymptomatic. In addition, they highlight new screening approaches to accurately identify these patients.

First nonprescription daily oral contraceptive pill, OTC opioid antagonist nasal spray for opioid overdose, and 5 more FDA-approved drugs primary care clinicians should know about.

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.

Robert Busch, MD, discusses common screening methods to detect chronic kidney disease (CKD) and how he utilizes the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in his practice.

Dhiren Patel, PharmD, and Robert Busch, MD, present an overview of chronic kidney disease (CKD) and how it may impact a patient.

Your daily dose of the clinical news you may have missed.

Results from a new study of Medicare beneficiaries admitted for an emergency general surgery show the odds of 30-day readmission was 67% lower for those with follow-up visit.

Empagliflozin is approved to lower the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.